ANN ARBOR, MI -- (MARKET WIRE) -- January 09, 2007 -- Pipex Pharmaceuticals, Inc. (OTCBB: PPXP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced the publication of preclinical results of its lead drug candidate, COPREXA™ (oral tetrathiomolybdate), in the protection against doxorubicin-induced cardiotoxicity as compared to existing FDA approved anti-copper therapies, such as zinc acetate. These results have been published in the journal Translation Research, 2006 Dec; Vol 148 (6);309-14.
